moneyheap
SYK · Analysis updated Nov 10, 2026, 6:00 PM ET
Why is Stryker Corporation (SYK) stock moving?
Stryker's third-quarter 2026 report (Oct 29) showed net sales up 7.7% to $6.5B, adjusted EPS up 10.3% to $3.52, and a $3.0B increase to the buyback, but management said growth fell short of its expectations. The stock closed 6.4% lower on Oct 30 at $291.86 on about 6.4M shares, roughly 2x recent volume. Most brokers then cut targets, moving to a range of $290 (TD Cowen) to $390 (Citizens), and Canaccord downgraded to Hold. The stock recovered to $306.81 by Nov 2 and jumped 9.4% to $339.65 on Nov 4 on 6.5M shares; the supplied news does not explain that move, and a shelf registration filed the same day had no disclosed terms. It has since drifted back to $324.29 (Nov 10), still about 4% above the pre-earnings close of $311.75 but roughly 4.5% below the Nov 4 peak. Across the 11 targets in the news, the median is about $336, roughly 3.5% above the current price. Piper Sandler's raise to $350 on Nov 9 and the Jim Davis board nomination are constructive, but the CEO transition (Spencer Stiles succeeds Kevin Lobo on Jan 1, 2027) and the slower organic growth keep the outlook mixed.
News behind the analysis
- Piper Sandler Maintains Overweight on Stryker, Raises Price Target to $350Piper Sandler kept its Overweight rating and raised its price target from $325 to $350 after the third-quarter report.
- Stryker Announces Intention to Nominate Jim Davis to Board of DirectorsStryker's board nominated Jim Davis, Chairman, CEO and President of Quest Diagnostics, for election effective January 1, 2027.
- Stryker Files Prospectus For Offering Mixed Shelf; Terms UndisclosedStryker filed a mixed shelf registration for a possible future securities offering; no terms were disclosed.
- Truist Securities Reiterates Hold on Stryker, Lowers Price Target to $305Truist kept its Hold rating and cut its price target to $305 following the quarter.
- Stifel Maintains Buy on Stryker, Lowers Price Target to $325Stifel kept its Buy rating but lowered its price target to $325 after the third-quarter results.
- Rothschild & Co Redburn Adjusts Price Target on StrykerRothschild & Co Redburn lowered its Stryker price target to $336 from $360.
- Stryker Reports Third Quarter 2026 Operating ResultsNet sales rose 7.7% to $6.5B and adjusted EPS rose 10.3% to $3.52, though management said growth fell short of its expectations. The board also approved a $3.0B increase to the buyback program.
- Canaccord Genuity Downgrades Stryker to Hold, Lowers Price Target to $300Canaccord Genuity cut Stryker to Hold from Buy and set a $300 price target after the quarter.
- RBC Capital Maintains Outperform on Stryker, Lowers Price Target to $375RBC kept its Outperform rating and lowered its price target to $375 after the third-quarter report.
- JP Morgan Maintains Overweight on Stryker, Lowers Price Target to $340JP Morgan kept its Overweight rating and lowered its price target to $340.
About Stryker Corporation
Stryker is a large medical technology company based in Portage, Michigan. It makes surgical equipment, orthopaedic implants, neurotechnology products and hospital equipment, and is known for its Mako robotic-arm system for joint replacement. Sales were about $25 billion in 2025.
How it makes money
Stryker sells its products mainly to hospitals and surgery centers, and it reports two segments. MedSurg and Neurotechnology is the larger one, roughly 60% of sales. It covers surgical instruments, endoscopy, medical beds and stretchers, emergency-care equipment, and devices for strokes and other brain and nerve conditions. Orthopaedics, roughly 40%, covers hip and knee implants, trauma and extremities products and spine products, plus Mako robot systems and their ongoing use. About three-quarters of sales come from the US. A large share of revenue repeats over time from disposables and implants used in each procedure.
What usually moves SYK
- Number of elective surgeries, especially hip and knee replacements
- Hospital spending on new equipment
- Adoption of Mako robotic surgery
- Acquisitions and how well they are integrated
- Pricing pressure, tariffs and currency moves